Plasma Protein Biomarkers and Long-Term Cardiovascular Mortality Risk in Patients With Chronic Coronary Heart Disease

Protein biomarkers that reflect different pathophysiological pathways have been associated with the risk of adverse cardiovascular events. However, it is uncertain whether these associations are sustained with increasing years after the biomarkers are measured. In this cohort study, 7745 patients wi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Heart Association 2024-11, Vol.13 (21), p.e034367
Main Authors: Stewart, Ralph A H, Robledo, Kristy P, Tonkin, Andrew M, Keech, Anthony, Kritharides, Leonard, Marschner, Ian, Janus, Edward, Thompson, Peter L, Watts, Gerald F, Zeller, Tanja, White, Harvey D, Simes, John
Format: Article
Language:English
Subjects:
Adrenomedullin - blood
Aged
biomarkers
Biomarkers - blood
Blood Proteins
C-Reactive Protein - analysis
C-Reactive Protein - metabolism
cardiovascular risk
Chronic Disease
Coronary Disease - blood
Coronary Disease - mortality
coronary heart disease
Cystatin C - blood
death
Female
Fibrin Fibrinogen Degradation Products - analysis
Fibrin Fibrinogen Degradation Products - metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
long‐term survival
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Pravastatin - therapeutic use
Protein Precursors
Risk Assessment
Risk Factors
Time Factors
Troponin I - blood
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein biomarkers that reflect different pathophysiological pathways have been associated with the risk of adverse cardiovascular events. However, it is uncertain whether these associations are sustained with increasing years after the biomarkers are measured. In this cohort study, 7745 patients with coronary heart disease who participated in the LIPID (Long-Term Intervention With Pravastatin in Ischemic Disease) trial, BNP (B-type natriuretic peptide), troponin I, cystatin-C, C-reactive protein, d-dimer and midregional proadrenomedullin were measured at baseline and after 1 year. Discrimination of plasma biomarker concentrations for cardiovascular death were evaluated in landmark analyses from 1 year for the next 5 years of the randomized trial, and for 10 additional years after trial completion. All 6 biomarkers were associated with risk of cardiovascular death (n=1903) both during and after the clinical trial (each
ISSN:2047-9980
2047-9980
DOI:10.1161/JAHA.123.034367